Strategic approaches to developing drug treatments for ALS
- 31 January 2008
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 13 (1-2) , 67-72
- https://doi.org/10.1016/j.drudis.2007.10.011
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- Ethnic variation in the incidence of ALSNeurology, 2007
- β-Lactam antibiotics are multipotent agents to combat neurological diseasesBiochemical and Biophysical Research Communications, 2005
- Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALSNature Medicine, 2005
- Molecular Diagnosis and Biomarker Identification on SELDI proteomics data by ADTBoost method2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), 2005
- Teaching old drugs new tricksTrends in Neurosciences, 2002
- Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in miceNature, 2002
- Neuronal survival following remote adenovirus gene deliveryJournal of Neurosurgery: Spine, 2002
- Neuron-Specific Expression of Mutant Superoxide Dismutase 1 in Transgenic Mice Does Not Lead to Motor ImpairmentJournal of Neuroscience, 2001
- Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions.Proceedings of the National Academy of Sciences, 1996
- Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosisAnnals of Neurology, 1995